ClinicalTrials.gg
Not yet recruitingNCT07661407Updated Jun 29, 2026

High-Intensity Laser Therapy (HILT) in Patients With Knee Osteoarthritis

An interventional study of Conventional Physiotherapy and High-Intensity Laser Therapy (HILT) in Knee Osteoarthritis (Knee OA), sponsored by University of Rzeszow. Not yet recruiting. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by University of Rzeszow · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This randomized placebo-controlled trial aims to evaluate the effectiveness of High-Intensity Laser Therapy (HILT) as an adjunct to standard outpatient physiotherapy in patients with knee osteoarthritis. Seventy-two participants will be randomly assigned to receive either conventional physiotherapy combined with active HILT or conventional physiotherapy combined with sham HILT. Outcomes related to pain, knee function, physical performance, muscle strength, range of motion, psychosocial factors, quality of life and body composition will be assessed at baseline, after the intervention, and at 8-week follow-up.

Read the detailed description

Knee osteoarthritis is one of the leading causes of pain and disability among older adults. Although physiotherapy constitutes a cornerstone of conservative management, the clinical effectiveness of High-Intensity Laser Therapy remains uncertain due to methodological heterogeneity of available studies. This prospective randomized placebo-controlled trial will evaluate whether HILT provides additional benefits when combined with standard physiotherapy.

Participants aged 40-75 years with radiographically confirmed mild-to-moderate knee osteoarthritis and pain intensity of at least 4 points on the Visual Analogue Scale will be enrolled. Participants will be randomly assigned in a 1:1 ratio using block randomization. The intervention period will last two weeks. Both groups will receive the same physiotherapy programme consisting of aerobic, strengthening, balance, proprioceptive, stretching, gait and functional exercises. The experimental group will receive active HILT, whereas the control group will receive sham HILT.

Assessments will be performed at baseline, immediately after treatment and 8 weeks after treatment completion.

02

Conditions studied

  • Knee Osteoarthritis (Knee OA)

Keywords

  • High-Intensity Laser Therapy
  • HILT
  • Knee Osteoarthritis
  • Gonarthrosis
  • Physiotherapy
  • Pain
  • KOOS
  • Randomized Controlled Trial
03

In context

Osteoarthritis, Knee

3,292 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 72 is close to the median of 68 across 2,714 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

University of Rzeszow is the lead sponsor of 37 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Radiographically confirmed knee osteoarthritis
  • Mild-to-moderate disease severity
  • Pain ≥4 on VAS for at least 3 months
  • Ability to participate in physiotherapy

Exclusion criteria

Exclusion Criteria:

  • Advanced OA requiring surgery
  • Previous knee arthroplasty
  • Knee instability
  • Acute inflammation
  • Neurological disorders affecting gait
  • Neuropathies or myopathies
  • Active inflammatory arthritis
  • Recent lower-limb injury (\<6 months)
  • Intra-articular injections within 3 months
  • Cancer, pregnancy, epilepsy
  • Electronic implants or pacemaker
  • Active local infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Conventional Physiotherapy + HILT

    Behavioral: Conventional Physiotherapy · Device: High-Intensity Laser Therapy (HILT)

  • Sham comparator
    Conventional Physiotherapy + Sham HILT

    Behavioral: Conventional Physiotherapy · Device: Sham High-Intensity Laser Therapy

Interventions

  • BehavioralConventional Physiotherapy

    Participants will receive a standardized outpatient physiotherapy programme delivered five times per week for two consecutive weeks. Each session will include aerobic exercise on a stationary bicycle, strengthening exercises, balance and proprioceptive training, functional exercises, stretching exercises, postural exercises, and gait training. The physiotherapy programme will be identical in both study groups.

  • DeviceHigh-Intensity Laser Therapy (HILT)

    Participants will receive High-Intensity Laser Therapy using the ASA Laser HIRO 3.0 device (3 kW). Treatment will be administered three times per week for two consecutive weeks, resulting in six treatment sessions. Laser irradiation will be delivered in pulsed mode at a frequency of 20 Hz with a total energy dose of 3000 J per session. The laser will be applied using a dynamic scanning technique over the anterior, medial, and lateral aspects of the affected knee joint and selected periarticular trigger points. All procedures will be performed according to a standardized treatment protocol.

    Also known as: ASA Laser HIRO 3.0, HILT

  • DeviceSham High-Intensity Laser Therapy

    o Participants will undergo a sham High-Intensity Laser Therapy procedure using the same ASA Laser HIRO 3.0 device and treatment schedule as the active intervention group. The handpiece will be positioned and moved over the treatment area in the same manner as during active treatment; however, no therapeutic laser energy will be delivered. The device will not emit laser radiation, light signals, or audible treatment sounds. Session frequency, duration, therapist-patient interaction, and treatment environment will be identical to those of the active HILT group.

    Also known as: Sham HILT, Placebo HILT

06

What researchers measure

Primary outcomes

  1. Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Subscale Score

    The Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain subscale assesses knee pain using 9 items. Scores are transformed to a 0-100 scale, where 0 represents extreme knee pain and 100 represents no knee pain. Therefore, higher scores indicate a better outcome (less pain). The primary endpoint is the change in KOOS Pain subscale score from baseline.

    Time frame: Baseline, immediately after the 2-week intervention, and 8 weeks after completion of treatment.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07661407
Lead sponsor
University of Rzeszow
Responsible party
Paweł Nalborczyk (Principal Investigator, University of Rzeszow) — Principal investigator
First posted
Jun 22, 2026
Start date
Jul 3, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Jun 29, 2026

Study contacts

Paweł Nalborczyk, MSc PT
Contact
pnalborczyk@ur.edu.pl
+48691219338

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion